Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 97,052
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12616823 | Sustained release formulations in delivery devices | 🖼🧊📄§ | 2026-05-05 | 2039-09-10 | 0 | 31 |
| 12616646 | Use of rochelle salt | 🖼🧊📄§ | 2026-05-05 | 2041-12-15 | 0 | 31 |
| 12616742 | Recombinant heme oxygenase-1 (HO-1) for the treatment of sickle cell disease | 🖼🧊📄§ | 2026-05-05 | 2040-07-24 | 0 | 31 |
| 12616661 | Composition for type II diabetics and for use in providing sustained energy release over time | 🖼🧊📄§ | 2026-05-05 | 2039-03-07 | 0 | 31 |
| 12616662 | Lipid particles for nucleic acid delivery and clinical applications of same | 🖼🧊📄§ | 2026-05-05 | 2042-11-17 | 0 | 31 |
| 12616683 | Combination therapy for the treatment of gastrointestinal stromal tumors | 🖼🧊📄§ | 2026-05-05 | 2044-04-10 | 0 | 31 |
| 12616684 | Pulmonary fibrosis medicine containing pyrazole derivative | 🖼🧊📄§ | 2026-05-05 | 2041-03-23 | 0 | 31 |
| 12616704 | Cannabichromene formulation for pain management | 🖼🧊📄§ | 2026-05-05 | 2041-03-31 | 0 | 31 |
| 12616705 | Use of cannabinoids in the treatment of Angelman syndrome | 🖼🧊📄§ | 2026-05-05 | 2043-05-02 | 0 | 31 |
| 12616706 | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations | 🖼🧊📄§ | 2026-05-05 | 2040-03-06 | 0 | 31 |
| 12616720 | Cell preparation for extemporaneous use, useful for healing and rejuvenation in vivo | 🖼🧊📄§ | 2026-05-05 | 2042-06-10 | 0 | 31 |
| 12616756 | Dimeric antibodies | 🖼🧊📄§ | 2026-05-05 | 2044-08-16 | 0 | 31 |
| 12616757 | Compositions and methods for correction of heritable ocular disease | 🖼🧊📄§ | 2026-05-05 | 2041-04-14 | 0 | 31 |
| 12616758 | Freeze-dried composition for preparing calibrated gas-filled microvesicles | 🖼🧊📄§ | 2026-05-05 | 2040-06-24 | 0 | 31 |
| 12616759 | Uses of labeled HSP90 inhibitors | 🖼🧊📄§ | 2026-05-05 | 2043-01-31 | 0 | 31 |
| 12616760 | Synthetic cyclic peptide mimetics | 🖼🧊📄§ | 2026-05-05 | 2041-09-13 | 0 | 31 |
| 12616761 | CXCR4-targeting compounds | 🖼🧊📄§ | 2026-05-05 | 2044-06-27 | 0 | 31 |
| 12616741 | Therapeutic combination comprising a pulmonary surfactant and a steroid for the prophylaxis of BPD | 🖼🧊📄§ | 2026-05-05 | 2041-03-17 | 0 | 31 |
| RE050878 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | 🖼🧊📄§ | 2026-05-05 | 2043-04-06 | 0 | 31 |
| RE050880 | Anti-human OX40L antibodies and methods of treatment | 🖼🧊📄§ | 2026-05-05 | 2042-08-01 | 0 | 31 |
| 12618055 | Hyaluronidase variants with improved stability and pharmaceutical composition comprising the same | 🖼🧊📄§ | 2026-05-05 | 2041-01-25 | 0 | 31 |
| 12618832 | Identification of cognate pairs of ligands and receptors | 🖼🧊📄§ | 2026-05-05 | 2039-12-19 | 0 | 31 |
| 12618840 | Antibody for detecting acetylation of COX2 protein, and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2040-09-18 | 0 | 31 |
| 12618024 | Microcell systems for controlled release of fragrances | 🖼🧊📄§ | 2026-05-05 | 2042-12-20 | 0 | 31 |
| 12618044 | Specification of functional cranial placode derivatives from human pluripotent stem cells | 🖼🧊📄§ | 2026-05-05 | 2042-12-21 | 0 | 31 |
| 12618059 | Anc80 encoding sphingolipid-metabolizing proteins | 🖼🧊📄§ | 2026-05-05 | 2039-03-07 | 0 | 31 |
| 12618060 | Nucleic acid molecules | 🖼🧊📄§ | 2026-05-05 | 2041-03-15 | 0 | 31 |
| 12618065 | MiRNA detargeting system for tissue specific interference | 🖼🧊📄§ | 2026-05-05 | 2038-10-02 | 0 | 31 |
| 12618066 | Promoter having high activity in activated T-cell | 🖼🧊📄§ | 2026-05-05 | 2040-11-13 | 0 | 31 |
| 12618067 | Targeted delivery of an inhibitor of miR-21 to macrophages for the treatment of pulmonary fibrosis | 🖼🧊📄§ | 2026-05-05 | 2041-04-09 | 0 | 31 |
| 12618070 | Increasing Atoh1 life to drive sensorineural hair cell differentiation | 🖼🧊📄§ | 2026-05-05 | 2042-03-04 | 0 | 31 |
| 12618076 | Methods of engineering platelets for targeting circulating tumor cells | 🖼🧊📄§ | 2026-05-05 | 2040-09-30 | 0 | 31 |
| 12618082 | Engineered muscle targeting compositions | 🖼🧊📄§ | 2026-05-05 | 2042-03-29 | 0 | 31 |
| 12617727 | Method for producing zirconia sintered body | 🖼🧊📄§ | 2026-05-05 | 2040-12-18 | 0 | 31 |
| 12617762 | Carboxy derivatives with antiinflamatory properties | 🖼🧊📄§ | 2026-05-05 | 2040-12-23 | 0 | 31 |
| 12617765 | Cannabinoid derivatives | 🖼🧊📄§ | 2026-05-05 | 2040-11-27 | 0 | 31 |
| 12617766 | Crystal form of thiophene derivative and preparation method therefor | 🖼🧊📄§ | 2026-05-05 | 2042-04-21 | 0 | 31 |
| 12617782 | Pyridazinones as PARP7 inhibitors | 🖼🧊📄§ | 2026-05-05 | 2043-05-12 | 0 | 31 |
| 12617783 | Heterocyclic GLP-1R agonists | 🖼🧊📄§ | 2026-05-05 | 2045-03-28 | 0 | 31 |
| 12617790 | Mitragynine analogs and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-06-24 | 0 | 31 |
| 12617801 | Tetrahydrothieno pyridine derivatives as DDRS inhibitors | 🖼🧊📄§ | 2026-05-05 | 2042-03-25 | 0 | 31 |
| 12617805 | Codrug that disintegrates in intestine, preparation therefor, and use thereof | 🖼🧊📄§ | 2026-05-05 | 2041-07-19 | 0 | 31 |
| 12617807 | Long lasting opioid reversal using hydrogen peroxide-induced release in blood | 🖼🧊📄§ | 2026-05-05 | 2042-04-01 | 0 | 31 |
| 12617809 | Cardioprotective lipid and method of use | 🖼🧊📄§ | 2026-05-05 | 2042-09-22 | 0 | 31 |
| 12617811 | HPK1 inhibitors and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-07-02 | 0 | 31 |
| 12617812 | Platinum(IV) complexes, methods of manufacture, compositions containing, and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2042-05-25 | 0 | 31 |
| 12617818 | Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them | 🖼🧊📄§ | 2026-05-05 | 2041-03-25 | 0 | 31 |
| 12617820 | Engineered coronavirus spike (s) protein and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2041-05-28 | 0 | 31 |
| 12617822 | Arc-based capsids and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2042-10-13 | 0 | 31 |
| 12617825 | Methods and compositions for reducing the immunogenicity of chimeric notch receptors | 🖼🧊📄§ | 2026-05-05 | 2042-04-08 | 0 | 31 |
Page 1Next →